Goldman Sachs
TEVA icon

Goldman Sachs’s Teva Pharmaceuticals TEVA Stock Holding History

Goldman Sachs’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$145M Sell
4,826,245
-1,051,822
-18% -$33.8M 0.02% 835
2025
Q4 		$183M Buy
5,878,067
+792,448
+16% +$19.5M 0.02% 674
2025
Q3 		$103M Buy
5,085,619
+202,825
+4% +$3.56M 0.01% 927
2025
Q2 		$81.8M Buy
4,882,794
+917,537
+23% +$14.8M 0.01% 1019
2025
Q1 		$60.9M Buy
3,965,257
+448,418
+13% +$8.01M 0.01% 1104
2024
Q4 		$77.5M Sell
3,516,839
-641,489
-15% -$11.7M 0.01% 965
2024
Q3 		$74.9M Sell
4,158,328
-132,319
-3% -$2.32M 0.01% 949
2024
Q2 		$69.7M Buy
4,290,647
+746,787
+21% +$11.5M 0.01% 963
2024
Q1 		$50M Sell
3,543,860
-261,488
-7% -$3.3M 0.01% 1172
2023
Q4 		$39.7M Sell
3,805,348
-633,945
-14% -$5.92M 0.01% 1345
2023
Q3 		$45.3M Sell
4,439,293
-110,540
-2% -$1.03M 0.01% 1157
2023
Q2 		$34.3M Sell
4,549,833
-105,278
-2% -$854K 0.01% 1379
2023
Q1 		$41.2M Sell
4,655,111
-683,033
-13% -$6.75M 0.01% 1207
2022
Q4 		$48.7M Buy
5,338,144
+118,979
+2% +$1.04M 0.01% 1194
2022
Q3 		$42.1M Buy
5,219,165
+400,197
+8% +$3.54M 0.01% 1235
2022
Q2 		$36.2M Buy
4,818,968
+1,425,393
+42% +$12.4M 0.01% 1374
2022
Q1 		$31.9M Sell
3,393,575
-705,599
-17% -$5.89M 0.01% 1674
2021
Q4 		$32.8M Buy
4,099,174
+837,955
+26% +$7.56M 0.01% 1679
2021
Q3 		$31.8M Sell
3,261,219
-678,213
-17% -$6.35M 0.01% 1645
2021
Q2 		$39M Sell
3,939,432
-216,456
-5% -$2.29M 0.01% 1478
2021
Q1 		$48M Sell
4,155,888
-867,490
-17% -$9.95M 0.01% 1200
2020
Q4 		$48.5M Buy
5,023,378
+484,420
+11% +$4.64M 0.01% 1147
2020
Q3 		$40.9M Buy
4,538,958
+1,391,151
+44% +$14.7M 0.01% 1155
2020
Q2 		$38.8M Buy
3,147,807
+58,920
+2% +$666K 0.01% 1170
2020
Q1 		$27.7M Buy
3,088,887
+560,530
+22% +$5.74M 0.01% 1270
2019
Q4 		$24.8M Sell
2,528,357
-292,434
-10% -$2.61M 0.01% 1688
2019
Q3 		$19.4M Sell
2,820,791
-712,989
-20% -$5.46M 0.01% 1806
2019
Q2 		$32.6M Buy
3,533,780
+954,670
+37% +$11.5M 0.01% 1467
2019
Q1 		$40.4M Buy
2,579,110
+391,431
+18% +$6.9M 0.01% 1303
2018
Q4 		$33.7M Buy
2,187,679
+228,622
+12% +$4.69M 0.01% 1388
2018
Q3 		$42.2M Sell
1,959,057
-1,138,993
-37% -$26.4M 0.01% 1349
2018
Q2 		$75.3M Sell
3,098,050
-1,768,329
-36% -$36.1M 0.02% 933
2018
Q1 		$83.2M Buy
4,866,379
+1,377,896
+39% +$26.9M 0.02% 889
2017
Q4 		$66.1M Buy
3,488,483
+2,238,537
+179% +$33.7M 0.02% 1081
2017
Q3 		$22M Sell
1,249,946
-848,254
-40% -$19.1M 0.01% 1903
2017
Q2 		$69.7M Buy
2,098,200
+574,574
+38% +$17.8M 0.02% 1027
2017
Q1 		$48.9M Sell
1,523,626
-224,656
-13% -$7.67M 0.01% 1236
2016
Q4 		$63.4M Sell
1,748,282
-615,650
-26% -$24.6M 0.02% 1099
2016
Q3 		$109M Sell
2,363,932
-938,374
-28% -$49M 0.03% 669
2016
Q2 		$166M Sell
3,302,306
-778,110
-19% -$41.4M 0.05% 423
2016
Q1 		$218M Sell
4,080,416
-919,546
-18% -$54M 0.07% 306
2015
Q4 		$328M Buy
4,999,962
+2,865,756
+134% +$177M 0.1% 196
2015
Q3 		$120M Buy
2,134,206
+578,098
+37% +$37.5M 0.04% 523
2015
Q2 		$92M Buy
1,556,108
+4,339
+0.3% +$268K 0.03% 709
2015
Q1 		$96.7M Sell
1,551,769
-427,038
-22% -$24.8M 0.03% 661
2014
Q4 		$114M Buy
1,978,807
+507,477
+34% +$28.3M 0.04% 605
2014
Q3 		$79.1M Buy
1,471,330
+257,623
+21% +$13.6M 0.03% 766
2014
Q2 		$63.6M Sell
1,213,707
-557,154
-31% -$28.5M 0.02% 940
2014
Q1 		$93.6M Sell
1,770,861
-2,161,746
-55% -$99.9M 0.03% 646
2013
Q4 		$158M Buy
3,932,607
+481,604
+14% +$19M 0.05% 427
2013
Q3 		$130M Buy
3,451,003
+67,125
+2% +$2.62M 0.05% 468
2013
Q2 		$133M Buy
+3,383,878
New +$132M 0.05% 429

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's TEVA Position: Q1 2026 in Review

Goldman Sachs reduced its Teva Pharmaceuticals (TEVA) stake by 18% in Q1 2026, selling an estimated $33.8M and leaving 4,826,245 shares worth $145M. The position accounts for 0.02% of the portfolio, ranked #835.

Goldman Sachs first reported a position in TEVA in Q2 2013 and has held it in 52 quarters since. The position peaked at $328M in Q4 2015. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Goldman Sachs held 4,826,245 shares of Teva Pharmaceuticals worth $145M as of Q1 2026.
  • Goldman Sachs sold 1,051,822 Teva Pharmaceuticals shares in Q1 2026, an estimated $33.8M.
  • Teva Pharmaceuticals made up 0.02% of Goldman Sachs's portfolio in Q1 2026, its #835 holding.
  • Goldman Sachs first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Teva Pharmaceuticals position peaked at $328M in Q4 2015.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.